ArticleMolecular and cellular biology2012
A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.
Article in Molecular and cellular biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Expression and function of myelin expression factor 2 in hepatocellular carcinoma.BMC gastroenterology · 2023Article
- Lysine-Specific Demethylase 1 (LSD1) epigenetically controls osteoblast differentiation.PloS one · 2022Article
- Ischemic Heart Disease Selectively Modifies the Right Atrial Appendage Transcriptome.Frontiers in cardiovascular medicine · 2021Article
- Runx1 promotes murine erythroid progenitor proliferation and inhibits differentiation by preventing Pu.1 downregulation.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- A Systems-Level Analysis Reveals Circadian Regulation of Splicing in Colorectal Cancer.EBioMedicine · 2018Article
- H1.0 Linker Histone as an Epigenetic Regulator of Cell Proliferation and Differentiation.Genes · 2018Review
- Selective dissociation between LSD1 and GFI1B by a LSD1 inhibitor NCD38 induces the activation ofOncotarget · 2018Article
- Article
- Article
- C. elegans SUP-46, an HNRNPM family RNA-binding protein that prevents paternally-mediated epigenetic sterility.BMC biology · 2017Article
- Extracellular vesicles shed by melanoma cells contain a modified form of H1.0 linker histone and H1.0 mRNA-binding proteins.International journal of oncology · 2016Article
- MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO.PLoS genetics · 2016Article
- RUNX1B Expression Is Highly Heterogeneous and Distinguishes Megakaryocytic and Erythroid Lineage Fate in Adult Mouse Hematopoiesis.PLoS genetics · 2016Article
- Genetic and Epigenetic Mechanisms That Maintain Hematopoietic Stem Cell Function.Stem cells international · 2016Review
- Transcriptional Control of Stem and Progenitor Potential.Current stem cell reports · 2015Article
- NLS-tagging: an alternative strategy to tag nuclear proteins.Nucleic acids research · 2014Article
- Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal.Cell reports · 2014Article
- LMO2 induces T-cell leukemia with epigenetic deregulation of CD4.Experimental hematology · 2014Article
- Gata2 is required for HSC generation and survival.The Journal of experimental medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Funding
Abstract
RUNX1 is known to be an essential transcription factor for generating hematopoietic stem cells (HSC), but much less is known about its role in the downstream process of hematopoietic differentiation. RUNX1 has been shown to be part of a large transcription factor complex, together with LDB1, GATA1, TAL1, and ETO2 (N. Meier et al., Development 133:4913-4923, 2006) in erythroid cells. We used a tagging strategy to show that RUNX1 interacts with two novel protein partners, LSD1 and MYEF2, in erythroid cells. MYEF2 is bound in undifferentiated cells and is lost upon differentiation, whereas LSD1 is bound in differentiated cells. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) and microarray expression analysis were used to show that RUNX1 binds approximately 9,000 target sites in erythroid cells and is primarily active in the undifferentiated state. Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2. Knockdown of Myef2 expression in developing zebrafish results in a reduced number of HSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.